Let’s End Cancer
Cancer impacts people of every age—from infants to the elderly—across all communities.
More than 1,600 people die each day at the hands of this terrible disease. This number is unacceptable, and we are committed to funding innovative, early stage and established cancer research that promotes early detection, enhances treatment and improves outcomes.
We also focus on underfunded areas of research, including rare cancers, improving outcomes for underserved communities and children’s cancer. We emphasize collaboration amongst individuals and institutions; accessibility to clinical trials for underserved communities; and support tenacious, entrepreneurial scientists focused on the development of affordable, accessible treatments.
Did You Know?
Children’s cancer is one of the most neglected and underfunded areas of research.
Every year, the FDA approves on average 12 drugs to treat adult cancer but has only approved eight drugs to treat childhood cancers since 1978.
Learn more about our investments in the people and new ideas advancing cancer research toward a cure.
Applying for a Grant?
Grant proposals that demonstrate a commitment to collaboration across multiple departments or institutions receive priority. While grants are primarily focused on medical institutions located in the Pacific Northwest, we will occasionally consider proposals from other regions of the United States on a case-by-case basis. Endowments, publications, annual fund appeals or general operations are not eligible for funding.
Below are relevant resources and information to support your grant application.
Stepping Stones to Stability: Addressing Intersection of Homelessness and Intellectual Challenges|Read More
Over the years of working with homeless youth in the Seattle area, Ryther has recognized a pattern: young adults experiencing intellectual and developmental di…
PDX Pharmaceuticals Secures Additional Investment from the Kuni Foundation to Advance New Cancer-Fighting Precision TherapiesRead More
Portland, Oregon -- PDX Pharmaceuticals, a privately held company developing first-in-class nanotechnology-based therapies for treating cancer, received a seco…